Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

BACKGROUND: Researchers have not simultaneously compared the cost‐effectiveness of six immunotherapies with chemotherapy for advanced non‐small cell lung cancer. This study evaluated the cost‐effectiveness across different programmed death‐ligand 1 (PD‐L1) levels. METHODS: A Markov model with lifeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Szu‐Chun, Ou, Huang‐Tz, Su, Wu‐Chou, Wang, Shi‐Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134257/
https://www.ncbi.nlm.nih.gov/pubmed/36653947
http://dx.doi.org/10.1002/cam4.5632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134257/
https://www.ncbi.nlm.nih.gov/pubmed/36653947
http://dx.doi.org/10.1002/cam4.5632

Ejemplares similares